Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease

Coronary Artery Disease Clinical Trial

— RENOVATE  

Official title:

Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention (RENOVATE-COMPLEX-PCI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03381872
• Other study ID #: Renovate16453143
• Status: Completed
• Phase: N/A
• Start date: May 10, 2018
• Est. completion date: December 31, 2022

Study information

• Verified date: January 2023
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to compare clinical outcomes between intravascular imaging-guided versus angiography-guided percutaneous coronary intervention (PCI) in complex lesions.

Description:

After introduction of the 2nd generation drug-eluting stents (DES), the rates of device-related failure or target lesion failure such as restenosis and stent thrombosis has been markedly decreased, compared with the era of bare metal stents or 1st generation DES. Nevertheless, patients undergoing percutaneous coronary intervention (PCI) for complex lesions, for example, chronic total occlusion (CTO), left main disease, true bifurcation lesion, long lesion, multi-vessel PCI, multiple overlapping stents, or severely calcified lesions have significantly worse clinical outcomes than those with non-complex lesions.

During the PCI procedure, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on preintervention lesion characteristics, including vulnerable plaques, lesion severity, length, and morphology; on postintervention optimal stent implantation for stent expansion, extension, and apposition; and on possible complications after stent implantation. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial (RCT) and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the RCTs were limited with small sample size and dealt with very selected lesion subsets such as CTO or long lesion. Moreover, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI. Meanwhile, appropriate imaging modality may differ according to patient and lesion characteristics.

One of the ways to maximize the advantage of intravascular imaging is choice of intravascular imaging devices by the operator's discretion. Therefore, the current RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) is designed to investigate whether PCI under guidance of intravascular imaging devices (IVUS or OCT) chosen by operators would improve clinical outcomes compared with angiography-guided PCI in patients with complex lesions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1639
• Est. completion date: December 31, 2022
• Est. primary completion date: May 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Subject age =19 years old

• Coronary artery disease requiring PCI

• Patients with complex lesion

1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch =2.5mm size

2. Chronic total occlusion (=3 months) as target lesion

3. Unprotected LM disease PCI (LM ostium, body, distal LM bifurcation including non-true bifurcation)

4. Long coronary lesions (implanted stent =38 mm in length)

5. Multi-vessel PCI (=2 vessels treated at one PCI session)

6. Multiple stents needed (=3 more stent per patient)

7. In-stent restenosis lesion as target lesion

8. Severely calcified lesion (encircling calcium in angiography)

9. Ostial coronary lesion (LAD, LCX, RCA)

• Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion Criteria:

• Target lesions not amenable for PCI by operators' decision

• Cardiogenic shock (Killip class IV) at presentation

• Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus

• Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)

• Pregnancy or breast feeding

• Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)

• Unwillingness or inability to comply with the procedures described in this protocol.

Related Conditions & MeSH terms

• Atherosclerosis
• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Procedure:
• Percutaneous coronary intervention for complex lesion
In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms Intravascular imaging arm Angiography arm Definition of Complex Lesions True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch =2.5mm size Chronic total occlusion (=3 months) as target lesion PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation) Implanted stent length =38mm Multi-vessel PCI (=2 major epicardial coronary arteries treated at one PCI session) Multiple stent needed (=3 more stent per patient) In-stent restenosis lesion as target lesion Severely calcified lesion (encircling calcium in angiography) Ostial coronary lesion (LAD, LCX, RCA)

Device:
• Drug-eluting stent
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
• Intravascular imaging (IVUS or OCT)
IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of =180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm. [2] By measuring lumen diameter at the distal reference sites (in case of =180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm.
• Drug-coated balloon
All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Target vessel Failure	A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization	1-year after last patient enrollment
Secondary	Target vessel failure without procedure-related MI	A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization	1-year after last patient enrollment
Secondary	Cardiac death or target-vessel related MI	Cardiac death or target-vessel related MI	1-year after last patient enrollment
Secondary	All-cause death	any death	1-year after last patient enrollment
Secondary	Cardiac death	cardiac death	1-year after last patient enrollment
Secondary	Target vessel MI with procedure-related MI	Target vessel MI with procedure-related MI	1-year after last patient enrollment
Secondary	Target vessel MI without procedure-related MI	Target vessel MI without procedure-related MI	1-year after last patient enrollment
Secondary	Any MI with procedure-related MI	Any MI with procedure-related MI	1-year after last patient enrollment
Secondary	Any MI without procedure-related MI	Any MI without procedure-related MI	1-year after last patient enrollment
Secondary	Non-target vessel related MI	Non-target vessel related MI	1-year after last patient enrollment
Secondary	Target lesion revascularization	TLR	1-year after last patient enrollment
Secondary	Target vessel revascularization	TVR	1-year after last patient enrollment
Secondary	Any revascularization	clinically-driven revascularization	1-year after last patient enrollment
Secondary	Stent thrombosis	definite stent thrombosis	1-year after last patient enrollment
Secondary	Incidence of contrast-induced nephropathy	CIN was defined as an increase in serum creatinine of =0.5mg/dL or =25% from baseline within 48-72 hours after contrast agent exposure	48-72 hours after index procedure
Secondary	Total amount of contrast use	Total amount of contrast use during index hospitalization	Immediate after index procedure
Secondary	Total procedure time	Total procedure time during index hospitalization	Immediate after index procedure
Secondary	Total medical cost	Total medical cost	1-year after last patient enrollment